CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars:  On January 30, 2025, the European Medicines Agency (EMA) Committee ...

Request To Download Free Sample of This Strategic Report @- Report Ocean is delighted to unveil an exhaustive analysis of the Philippines Plant Breeding And CRISPR Plants Market, presenting a ...

EU regulators have issued a positive opinion for the extension of the market authorization for a subcutaneous formulation of Johnson & Johnson's (NYSE:JNJ) Rybrevant for the treatment of a certain ...

Health and Media Minister Dr. Nalinda Jayatissa directed the newly appointed members of the Ayurvedic Drug and Product Regulatory Council to ...

Doctors who were dragged into the Dengvaxia cases are hoping to get justice through the ongoing evaluation conducted by the ...

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...

EMA validates X4 Pharma’s marketing authorization application for mavorixafor to treat WHIM syndrome: Boston Monday, January 27, 2025, 11:00 Hrs [IST] X4 Pharmaceuticals, a comp ...

Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for ...

If approved by the EMA, mavorixafor would be the first drug indicated for patients with WHIM syndrome in Europe, a population ...

A lot of the products we use to treat redness and rosacea are similar, however, so while those on this list are formulated for skin with rosacea, they can also help skin that’s prone to redness.

R. China School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, P. R. China Key Laboratory of New Drug Discovery and Evaluation of the Guangdong Provincial Education Department, ...